GLP-3R (5 mg/vial)
$70.00
Retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, is surging in 2026 popularity for metabolic research, enabling studies on multi-pathway insulin sensitization, profound fat reduction, and energy expenditure in experimental models—ideal as a flagship for weight loss-focused labs seeking next-gen alternatives to dual agonists. For research use only. Not for human or veterinary use.
20 in stock
